We describe a patient with Stevens-Johnson syndrome (erythema multiforme major) associated with an increase in glipizide dosage administration. Glipizide is a second-generation sulfonylurea commonly used to treat patients with noninsulin-dependent diabetes mellitus. Although several reports have documented Stevens-Johnson syndrome caused by first-generation sulfonylureas, our case appears to be the first report of a second-generation sulfonylurea associated with Stevens-Johnson syndrome.
Get full access to this article
View all access options for this article.
References
1.
TayYK, HuffJC, WestonWL. Mycoplasma pneumoniae infection is associated with Stevens-Johnson syndrome, not erythema multiforme (von Hebra). J Am Acad Dermatol, 1996; 35:757-60.
2.
RoujeauJC, KellyJP, NaldiL, et al.Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med, 1995; 333:1600-7.
3.
DavisSN, GrannerDK. Insulin, oral hypoglycemic agents, and the pharmacology of the endocrine pancreas. In: HardmanJG, LimbirdLE, GilmanAG, editors. Goodman and Gilman's the pharmacological basis of therapeutics. New York: McGraw-Hill; 2001. p. 1701-4.
4.
SkillmanTG, FeldmanJM. The pharmacology of sulfonylureas. Am J Med, 1981; 70:361-72.
5.
Glipizide. In: Litt J, editor. Litt's drug eruption reference manual including drug interactions. London: Taylor & Francis; 2004. p.225.
6.
KanefskyTM, MedoffSJ. Stevens-Johnson syndrome and neutropenia with chlorpropamide therapy. Arch Intern Med, 1980; 140:1543.
7.
YaffeeH.Stevens-Johnson syndrome caused by chlorpropamide. Arch Dermatol, 1960; 82:636-7.
8.
TullettGL.Fatal case of toxic erythema after chlorpropamide (Diabinese). Br Med J, 1966; 5480:148.
9.
RothfeldEL, GoldmanJ, GoldbergHH, EinhornS. Severe chlorpropamide toxicity. JAMA, 1960; 104:54-5.
10.
RiederMJ, KrauseR, BirdIA. Time-course of toxicity of reactive sulfonamide metabolites. Toxicology, 1995; 95:141-6.
11.
SullivanJR, ShearNH. The drug hypersensitivity syndrome: what is the pathogenesis?. Arch Dermatol, 2001; 137:357-64.
12.
SvenssonCK, CowenEW, GaspariAA. Cutaneous drug reactions. Pharmacol Rev, 2001; 53:357-79.
13.
ShearNH, SpielbergSP, GrantDM, et al.Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Ann Intern Med, 1986; 105:179-87.
14.
WolkensteinP, CharueD, LaurentP, et al.Metabolic predisposition to cutaneous adverse drug reactions. Role in toxic epidermal necrolysis caused by sulfonamides and anticonvulsants. Arch Dermatol, 1995; 131:544-51.
15.
ReillyTP, JuC. Mechanistic perspectives on sulfonamide-induced cutaneous drug reactions. Curr Opin Allergy Clin Immunol, 2002; 2:307-15.
16.
UetrechtJP.New concepts in immunology relevant to idiosyncratic drug reactions: the “danger hypothesis” and innate immune system. Chem Res Toxicol, 1999; 12:387-95.
17.
KnowlesS, ShapiroL, ShearN.Should celecoxib be contra-indicated in patients who are allergic to sulfonamides?. Drug Saf, 2001; 24:239-47.
